In 2009, Chinese blood products market valued nearly RMB7 billion and it will continue to expand in the next two or three years. The main reasons include:

- The demand from the downstream of China blood products industry keeps growing.
- China has a large population, and the aging of which grows obviously severe
- The indications of blood products are increasing.
Due to the strong demand for albumin in China, the product structure of blood products in China distinguishes from foreign product structure which is dominated by coagulation factor. In 2009, in the product structure of blood products in China, albumin accounted for 68%, intravenous gammaglobulin 21% and coagulation factor 9%.

Product Structure of Blood Products in China, 2009

By the end of 2009, 33 Chinese manufacturers of blood products had obtained GMP certification, with the annual plasma volume of around 3,500 tons totally. However, only Hualan Biological Engineering Ltd, Beijing Tiantan Biological Products Co., Ltd, Shanghai RAAS Blood Products Co., Ltd, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd, Sino Biopharmaceutical Limited and CNBG Shanghai Institute of Biological Products have the annual plasma volume of over 300 tons respectively.
Hualan Biological Engineering Ltd, as a leading enterprise in China blood products industry, owns a lot of plasma stations and relatively abundant plasma resources with high utilization rate and many varieties. As of October 2010, Hualan Biological Engineering Ltd had had 18 plasma stations, including 13 plasma collection stations in operation, one being examined, 3 under construction and one to be built.

From January to August of 2010, human serum albumin, intravenous human immunoglobulin, tetanus human immunoglobulin, hepatitis B immunoglobulin, human immunoglobulin, human prothrombin complex, rabies immunoglobulin and human clotting Factor VIII of Hualan Biological Engineering Ltd were approved by National Institute for the Control of Pharmaceutical And Biological Products, with the total release volume of 2.272 million bottles.

From January to June of 2010, Hualan Biological Engineering Ltd achieved the revenue of RMB343 million from blood products (a 67% YoY rise), including RMB124 million from human serum albumin (a 13% YoY rise), RMB121 million from intravenous gammaglobulin (a 61% YoY rise) and RMB97.95 million from other products (a 38% YoY rise).

**Gross Margin of Hualan Biological Engineering Ltd (by Product), 2007-H1 2010**

Source: ResearchInChina, Hualan Biological Engineering Ltd
1 Profile of Blood Products
   1.1 Definition
   1.2 Classification
   1.3 Recombinant Blood Products
   1.4 Industry Chain
   1.5 Features

2 Overview of China Blood Products Industry
   2.1 General Overview
   2.2 Operating Environment
      2.2.1 International Market
      2.2.2 Policies
      2.2.3 Domestic Biopharmaceutical Market
   2.3 Plasma Volume
   2.4 Import & Export

3 Main Blood Product Markets
   3.1 Human Serum Albumin
   3.2 Intravenous Human Immunoglobulin
   3.3 Coagulation Factor
   3.4 Hepatitis B Immunoglobulin
   3.5 Human Immunoglobulin
   3.6 Human Prothrombin Complex
   3.7 Tetanus Immunoglobulin
   3.8 Rabies Immunoglobulin

4 Key Manufacturers in China
   4.1 Hualan Biological Engineering Ltd
      4.1.1 Profile
      4.1.2 Operation
      4.1.3 Blood Products
   4.2 Shanghai RAAS Blood Products Co., Ltd
      4.2.1 Profile
      4.2.2 Operation
      4.2.3 Strategies
   4.3 Beijing Tiantan Biological Products Co., Ltd
      4.3.1 Profile
      4.3.2 Operation
• 4.3.3 Blood Products
• 4.4 Sino Biopharmaceutical Limited
  • 4.4.1 Profile
  • 4.4.2 Operation
  • 4.4.3 Shandong Taibang Biological Products Co. Ltd
  • 4.4.4 Xi’an Hui Tian Blood Products Co. Ltd
  • 4.4.5 Guiyang Qianfeng Biological Product Liability Co., Ltd.
• 4.5 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd
  • 4.5.1 Profile
  • 4.5.2 Operation
• 4.6 CNBG Shanghai Institute of Biological Products
  • 4.6.1 Profile
  • 4.6.2 Operation
• 4.7 Shanxi Kangbao Biological Product Co., Ltd
  • 4.7.1 Profile
  • 4.7.2 Operation
• 4.8 Green Cross
  • 4.8.1 Profile
  • 4.8.2 Operation
• 4.9 Jiangxi Boya Biopharmaceutical Co., Ltd
  • 4.9.1 Profile
  • 4.9.2 Operation
Selected Charts

- Classification and Effects of Blood Products
- Comparison between Gene Recombinant Blood Products and Traditional Blood Products
- Blood Product Industry Chain
- Product Structure of Blood Products in China, 2009
- Product Structure of International Blood Products, 2009
- Market Shares of Blood Products Manufacturing Enterprises in China, 2009
- Product Lines Contrast of Blood Products Manufacturing Enterprises in China
- Global Blood Products Market Scale, 2003-2008
- Classification of Global Blood Products Manufacturing Enterprises
- Sales of Global Blood Products Giants, 2009
- Major Policies for Blood Products in China
- Sales Revenue and YoY Growth Rate of Biological and Biochemical Pharmacy in China, 2005-2009
- Annual Plasma Volume in China, 2002-2009
- Production of Blood Products Manufacturing Enterprises in China, 2009
- Major Manufacturers and Their Shares in Chinese Human Serum Albumin Market, 2009
- Major Manufacturers and Their Shares in Chinese Intravenous Human Immunoglobulin Market, 2009
- Per Capita Consumption of Intravenous Human Immunoglobulin in Some Countries and Regions, 2005
- Major Manufacturers and Their Shares in Chinese Human Clotting Factor VIII Market, 2009
• Major Manufacturers and Their Release Volume & Shares in Chinese Hepatitis B Immunoglobulin Market, 2009
• Major Manufacturers and Their Shares in Chinese Human Immunoglobulin Market, 2009
• Major Manufacturers and Their Shares in Chinese Human Prothrombin Complex Market, 2009
• Major Manufacturers and Their Release Volume in Chinese Tetanus Immunoglobulin Market, 2009
• Major Manufacturers and Their Release Volume in Chinese Rabies Immunoglobulin Market, 2009
• Operating Income and Net Income of Hualan Biological Engineering Ltd, 2006- H1 2010
• Operating Income of Hualan Biological Engineering Ltd (by Sector), 2007- H1 2010
• Operating Income of Hualan Biological Engineering Ltd (by Region), 2007-2009
• Gross Margin of Hualan Biological Engineering Ltd (by Product) , 2007- H1 2010
• Distribution of Plasma Collection Stations of Hualan Biological Engineering Ltd, by Oct. 2010
• Operating Income of Blood Products of Hualan Biological Engineering Ltd (by Product), 2007- H1 2010
• Operating Income and Net Income of Shanghai RAAS Blood Products Co., Ltd, 2006- H1 2010
• Operating Income of Shanghai RAAS Blood Products Co., Ltd (by Product), 2005- H1 2010
• Gross Margin of Shanghai RAAS Blood Products Co., Ltd (by Product), 2005-2009
• Plasma Volume of Shanghai RAAS Blood Products Co., Ltd, 2007-2011E
• Operating Income of Shanghai RAAS Blood Products Co., Ltd (by Region), 2008-2009
• Operating Income and Net Income of Beijing Tiantan Biological Products Co., Ltd, 2006- Q3 2010
• Operating Income of Beijing Tiantan Biological Products Co., Ltd (by Product), 2007-2009
• Gross Margin of Beijing Tiantan Biological Products Co., Ltd (by Product), 2007-2009
• Operating Income of Beijing Tiantan Biological Products Co., Ltd (by Region), 2007-2009
• Operating Income of Blood Products of Beijing Tiantan Biological Products Co., Ltd, 2007- H1 2010
• Operating Income and Gross Profit of Sino Biopharmaceutical Limited, 2007- Q2 2010
• Operating Income of Sino Biopharmaceutical Limited (by Product), 2007-2009
• Operating Income and Total Profit of Shandong Taibang Biological Products Co. Ltd, 2007-2008
• Operating Income and Total Profit of Xi’an Hui Tian Blood Products Co. Ltd, 2007-2008
• Operating Income and Total Profit of Guiyang Qianfeng Biological Product Liability Co., Ltd., 2007-2008
• Operating Income and Total Profit of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd, 2007-2008
• Operating Income and Total Profit of CNBG Shanghai Institute of Biological Products, 2007-2008
• Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2007-Aug 2010
• Operating Income and Total Profit of Shanxi Kangbao Biological Products Co., Ltd, 2007-2008
• Operating Income and Total Profit of Green Cross (China), 2007-2008
• Release Volume of Blood Products of Green Cross (China), 2007-Aug 2010
• Operating Income and Total Profit of Jiangxi Boya Biopharmaceutical Co., Ltd., 2007-2008
How to Buy

<table>
<thead>
<tr>
<th>Product details</th>
<th>How to Order</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single user</td>
<td>By email: <a href="mailto:report@researchinchina.com">report@researchinchina.com</a></td>
</tr>
<tr>
<td></td>
<td>By fax: 86-10-82601570</td>
</tr>
<tr>
<td></td>
<td>By online: <a href="http://www.researchinchina.com">www.researchinchina.com</a></td>
</tr>
<tr>
<td>Enterprise-wide</td>
<td></td>
</tr>
<tr>
<td>Publication date:</td>
<td></td>
</tr>
<tr>
<td>Sept. 2010</td>
<td></td>
</tr>
<tr>
<td>For more information, call our office in Beijing, China:</td>
<td></td>
</tr>
<tr>
<td>Tel: 86-10-82600828</td>
<td></td>
</tr>
<tr>
<td>Website: <a href="http://www.researchinchina.com">www.researchinchina.com</a></td>
<td></td>
</tr>
</tbody>
</table>